Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Emerging novel agents for the treatment of mastocytosis

Tracy George • 12 Jun 2022
EHA 2022
Chronic Myeloid Leukemia Leukemia Myeloproliferative Neoplasms Rare Diseases Systemic Mastocytosis Antibodies Avapritinib Brentuximab vedotin Cladribine Midostaurin

Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT comments on the movement from broad, cladribine-based regimens to novel, targeted tyrosine kinase inhibitors (TKIs) such as avapritinib, for the treatment of systemic mastocytosis. Dr George also comments on the future development of antibody-based therapies, emphasizing the importance of more selective agents with fewer side effects. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consultant, Cogent Blueprint

More from Tracy George

1:49
Unmet needs and challenges in mastocytosis
Tracy George • 12 Jun 2022
1:51
Responses to avapritinib in patients with advanced systemic mastocytosis
Tracy George • 12 Jun 2022
0:37
Emerging targeted agents in the field of mastocytosis
Tracy George • 1 Apr 2021
3:37
Changes in mast cell number & immunophenotype in patients with mastocytosis treated with avapritinib
Tracy George • 1 Apr 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals